Paid Rheumatoid Arthritis Clinical Trials
Rheumatoid arthritis clinical trials now enrolling. Access new biologic and JAK inhibitor treatments. Compensation up to $3,800 for qualifying participants.
Compensation
$1,800 - $3,800
Duration
24-52 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-75 years
- Diagnosis of rheumatoid arthritis (ACR/EULAR 2010 criteria)
- Active disease with at least 4 tender and 4 swollen joints
- Elevated inflammatory markers (CRP or ESR)
- Inadequate response to at least one DMARD
- Stable DMARD therapy for at least 4 weeks
Who May Not Qualify
- Other inflammatory arthritis conditions
- Active or latent tuberculosis
- History of serious infections requiring hospitalization
- Live vaccines within 4 weeks of study start
- Severe liver or kidney impairment
Frequently Asked Questions
What treatments are being studied for rheumatoid arthritis?
+
Current studies investigate new biologics targeting various inflammatory pathways (IL-6, TNF, CD20), JAK inhibitors, and combination therapies. Some studies also explore treatments for patients who have failed multiple prior therapies.
Can I continue my current RA medications?
+
Many studies allow you to continue background therapy like methotrexate. Biologic medications typically need to be stopped before enrolling, with specific washout periods depending on the drug.
How is disease activity measured during the study?
+
Disease activity is assessed using standardized measures including joint counts, blood tests for inflammation, patient questionnaires, and sometimes imaging studies like ultrasound or MRI.
What if the study treatment does not work for me?
+
If you do not respond adequately to study treatment, you may be eligible to switch to a different arm of the study or receive rescue therapy. The study team will work with you to ensure you receive appropriate care.